MXPA05010859A - Antagonistas mchr1 heterociclicos. - Google Patents

Antagonistas mchr1 heterociclicos.

Info

Publication number
MXPA05010859A
MXPA05010859A MXPA05010859A MXPA05010859A MXPA05010859A MX PA05010859 A MXPA05010859 A MX PA05010859A MX PA05010859 A MXPA05010859 A MX PA05010859A MX PA05010859 A MXPA05010859 A MX PA05010859A MX PA05010859 A MXPA05010859 A MX PA05010859A
Authority
MX
Mexico
Prior art keywords
heterocyclic
mchr1 antagonists
mchr1
antagonists
11cby
Prior art date
Application number
MXPA05010859A
Other languages
English (en)
Spanish (es)
Inventor
Huiqiang Zhou
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MXPA05010859A publication Critical patent/MXPA05010859A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA05010859A 2003-04-11 2004-04-06 Antagonistas mchr1 heterociclicos. MXPA05010859A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46229203P 2003-04-11 2003-04-11
PCT/US2004/010518 WO2004092181A1 (en) 2003-04-11 2004-04-06 Heterocyclic mchr1 antagonists

Publications (1)

Publication Number Publication Date
MXPA05010859A true MXPA05010859A (es) 2005-12-14

Family

ID=33299933

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010859A MXPA05010859A (es) 2003-04-11 2004-04-06 Antagonistas mchr1 heterociclicos.

Country Status (8)

Country Link
US (1) US20060194871A1 (enExample)
EP (1) EP1618112A1 (enExample)
JP (1) JP2006522812A (enExample)
AR (1) AR044011A1 (enExample)
CA (1) CA2521832A1 (enExample)
MX (1) MXPA05010859A (enExample)
TW (1) TW200510429A (enExample)
WO (1) WO2004092181A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5000490B2 (ja) * 2005-04-28 2012-08-15 武田薬品工業株式会社 チエノピリミドン化合物
WO2007011285A1 (en) * 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
EP1937683A4 (en) * 2005-09-23 2010-08-25 Coley Pharm Group Inc PROCESS FOR 1H-IMIDAZO [4,5-C] PYRIDINES AND ANALOGUE THEREOF
KR101020333B1 (ko) 2005-09-30 2011-03-09 에프. 호프만-라 로슈 아게 Ｍｃｈ 수용체 길항제로서의 인단 유도체
AR056155A1 (es) * 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007093364A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
CA2636617A1 (en) * 2006-02-15 2007-08-23 Lothar Schwink Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2007146758A2 (en) * 2006-06-08 2007-12-21 Eli Lilly And Company Novel mch receptor antagonists
CN101460503A (zh) * 2006-06-08 2009-06-17 伊莱利利公司 新的mch受体拮抗剂
US20070299062A1 (en) * 2006-06-26 2007-12-27 The Procter & Gamble Company Melanin concentrating hormone antagonists
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
JP2010501553A (ja) 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体
CN101679348A (zh) 2007-01-10 2010-03-24 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
US8198307B2 (en) * 2007-05-11 2012-06-12 Korea Research Institute Of Chemical Technology Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same
ATE544759T1 (de) 2007-07-21 2012-02-15 Albany Molecular Res Inc 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AR075401A1 (es) 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
EP2848621A4 (en) * 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC RING CONNECTION
KR101551313B1 (ko) * 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
US11447486B2 (en) 2014-07-31 2022-09-20 Institut Pasteur Korea 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors
CN106866545B (zh) * 2017-03-31 2019-07-09 枣庄学院 1-环烷烃-5-硝基-1h-苯并[d]咪唑类化合物及其制备方法
CN107445899A (zh) * 2017-07-19 2017-12-08 枣庄学院 一种苯并咪唑类化合物及其制备方法
CN109020895B (zh) * 2018-08-07 2020-04-24 枣庄学院 一种金属催化的1-苄胺基取代苯并咪唑的合成方法
EP4132935A1 (en) * 2020-04-08 2023-02-15 Remix Therapeutics Inc. Compounds and methods for modulating splicing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1285651B1 (en) * 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
WO2002006245A1 (en) * 2000-07-05 2002-01-24 Synaptic Pharmarceutical Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
TW200510429A (en) 2005-03-16
WO2004092181A9 (en) 2005-01-27
AR044011A1 (es) 2005-08-24
CA2521832A1 (en) 2004-10-28
WO2004092181A1 (en) 2004-10-28
US20060194871A1 (en) 2006-08-31
EP1618112A1 (en) 2006-01-25
JP2006522812A (ja) 2006-10-05

Similar Documents

Publication Publication Date Title
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
UA83659C2 (ru) Антагонисты рецепторов p2x7 и их применение, фармацевтическая композиция на их основе, способ их получения (варианты)
MXPA05010137A (es) Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
MY137535A (en) New pyrrolidinium derivatives
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
ATE300533T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
IL150085A0 (en) New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
TW200613243A (en) Novel compounds
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
MX2007010414A (es) Derivados de piridin-2-carboxamida como antagonistas de mglur5.
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
ATE352543T1 (de) Ein dioxino(2,3-g)chinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
MXPA05011243A (es) Benzopiranos substituidos como agonistas selectivos del receptor beta de estrogeno.
PT1673354E (pt) Arilindenopiridinas e arilindenopirimidinas e sua utilização como antagonistas do receptor da adenosina a2a
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação